主要活动:管理服务对 MD 平台的访问,包括合同问题。选择过程将优先考虑开发用于罕见疾病儿科心脏病学的 MD 的服务请求。在这个组中,我们已经确定了 3 个服务请求(分别为案例研究 1-3、WP 3-5)。
3.1.12。2'-O,4'-C-甲基 - p-thio-adenylyl-(3'→5')-2'-O,4'-c-甲基 - 甲基 - thio-thio-guanylyl-(3'→5'→5')-2'-o 5′)-2′-deoxy-P-thio-adenylyl-(3′ → 5′)-2′-deoxy-P- thio-thymidylyl-(3′ → 5′)-2′-deoxy-P-thio-guanylyl-(3′ → 5′)-2′-deoxy-P-thio-guanylyl-(3′ → 5′)- 2'-脱氧 - thio-cytidylyl-(3'→5')-2'-脱氧 - 氧基-p- thio-adenylyl-(3'→5') - 2'-二氧基 - deoxy-pthio-tio-cytidyllyl-(3'→5'→5'→5') - 2'-二氧基) - 2'-二氧化物 - 2'氧基 - thio-phio-thio-thyly-nyly-nyly-(3'ioll-lyl-(3) 5′)-2′-deoxy-P-thio-thymidylyl-(3′ → 5′)- 2′-deoxy-P- thio-cytidylyl-(3′ → 5′)-2′-deoxy-P-thio-thymidylyl-(3′ → 5′)-2′-O, 4′-C-methylene-5-methyl-P- thio-cytidylyl-(3′ → 5′)-2′-O, 4′-C-methylene-5-methyl-P-thio-uridylyl-(3′ → 5′)-2′-O, 4′-C- methylene-5-methyl-P-thio-uridylyl-(3′ → 5′)-2′-O, 4′-C-methyleneguanosine, heptadecasodium salt - Orphan - EMEA-003595-PIP01-24 ............................................ 32